

September 3, 2019



## **DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference**

MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis, Minnesota.

Rick Pauls, President and CEO of DiaMedica Therapeutics will host one-on-one institutional investor meetings throughout the day at the event.

### **Dougherty & Co. Institutional Investor Conference**

**Date:** Thursday, September 5, 2019

**Location:** Millennium Hotel (1313 Nicollet Mall, Minneapolis, MN 55403)

### ***About DiaMedica Therapeutics Inc.***

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC."

For more information, please visit [www.diamedica.com](http://www.diamedica.com).

### **Contact:**

Scott Kellen  
Chief Financial Officer  
Phone: (763) 496-5118  
[skellen@diamedica.com](mailto:skellen@diamedica.com)



Source: DiaMedica Therapeutics Inc.